OBJECTIVE: To examine whether physicians' practice specialties are associated with the types of anti-diabetic treatments for patients with type 2 diabetes (T2D). METHODS: A retrospective study design was used based. All T2D patients' (N = 1,819,323) medication histories in a 12 month period were examined and classified into 9 treatment types (no anti-diabetic medication, oral anti-diabetic medication (OAD), basal insulin only, prandial insulin only, basal insulin with OAD, prandial insulin with OAD, basal/prandial insulin, basal/prandial insulin(including premixed insulins) with OAD, other insulin regimens). Physicians practice specialties were classified into five categories (family medicine, internal medicine, other primary care specialists, endocrinologists, other specialties). A two-way contingency table was created with Chi-square test and Fisher's exact test to examine the possible association between physicians' practice specialty and the types of anti-diabetic treatments they prescribed. RESULTS: Both the Chi-square test and the Fisher's exact test had p < 0.0001, indicating that physicians' practice specialty and their patients' anti-diabetic treatment choices were statistically significantly associated. The contingency table suggests that the percent of patients receiving no anti-diabetic medications varied across specialties from 36.0% in patients who visited an endocrinologist to 49% and 52% in patients who visited a family medicine physician or internist, respectively. The percent of patients receiving OAD only varied across specialties from 33.1% in patients who visited an endocrinologist to 46.8% in patients who saw a family medicine physician, and 43.6% in patients under the care of an internist. And the percent of patients receiving insulin as part of their regimen varied across specialties from 4.12% in patients who visited a family medicine physician to 12.3% in patients who visited an endocrinologist. CONCLUSION: Physicians' practice specialty is strongly associated with anti-diabetic medications prescribed for patients with T2D. Further research to examine outcomes differences across physician specialties is needed.
treatments), four health state preference measures (HSPMs), which vary in theoretical constructs, are being collected. Our objectives were to compare baseline values of the feeling thermometer (FT), the Health Utilities Index, Mark 2 and Mark 3 (HUI-2 and HUI-3), and the SF-6D, derived from the Short Form 36 and to explore associations between each HSPM and 29 baseline clinical and demographic characteristics. METHODS: Participants (n = 2053) were randomly selected for the cost effectiveness sub-study of ACCORD. To compare the HSPMs, we determined correlations between the measures, by overall score and within each quartile range. We used multivariate regression models to identify relationships between clinical and demographic characteristics for each HSPM. RESULTS: The mean Ϯ standard deviation HSPMs were: FT = 0.756 Ϯ 0.167, HUI-2 = 0.823 Ϯ 0.146, HUI-3 = 0.712 Ϯ 0.260, and SF-6D = 0.684 Ϯ 0.085. Although all 4 measures were significantly correlated with each other (Spearman r = 0.29-0.84 (p < 0.0001); relationships were weaker between the FT and the other measures (0.29-0.38) and strongest between the two HUI measures (0.84). By quartiles of HSPM, significant correlations were more common at the lowest quartile. In multivariate regression analyses, we identified significant associations (p < 0.01) between HSPM values and age (positive), gender (lower for females), years of education (positive), and race (lower for non-white). Clinical characteristics inversely associated with HSPMs were duration of diabetes, current smoking, secondary cardiovascular disease, total cholesterol, waist circumference, and body mass index. Number of medications (blood pressure, glycemic, or lipid) were not significantly associated with HSPMs. Glycosylated hemoglobin values were inversely related to FT only. CONCLUSION: Our results suggest that the four instruments,result in different HSPM values. Relationships with clinical and demographic variables vary by HSPM. Therefore, results of cost-effectiveness results may be impacted by the specific HSPM applied.
PDB66 HEALTH CARE UTILISATION AND EXPENDITURES ASSOCIATED WITH TREATMENTS OF DIABETES MELLITUS WITHIN THE SLOVAK REPUBLIC
Tesar T 1 , Foltan V 1 , Ilavska A 2 1 Comenius University, Bratislava, Slovak Republic, 2 Railway Hospital, Bratislava, Slovak Republic OBJECTIVE: The aim of this study was to collect comparable and reliable data about consumption of drugs for treatment of diabetes mellitus in Slovakia during the period 1996-2006. METHODS: Data of wholesalers (following ATC/DDD), who are legally obliged provide this information to the Slovak Institute for Drug Control, was used for the analysis. The results were expressed in the numbers of the packages, finance units (€)
